BSE filing, NSE: GUJTHEM. Summary written from the filing by ALFA Finder's alert engine.
Gujarat Themis Biosyn Ltd: key numbers
- Share price
- ₹355.55
- Market cap
- ₹4,628 Cr
- Revenue (annual)
- ₹165.8 Cr
- Net profit (annual)
- ₹46.68 Cr
- P/E (TTM)
- 95.0×Sector 46.1×
- Promoter holding
- 59.33%-11.53% QoQ
- FII holding
- 3.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Themis Biosyn Ltd
All →Gujarat Themis Biosyn Board Meeting Date
Gujarat Themis Biosyn scheduled its board meeting for 4 Nov 2026 to approve Q2 and H2 un-audited results. No financial figures are disclosed in this advance intimation.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn clarified that its 9 October 2026 credit-rating intimation was uploaded in error and should be disregarded. No substantive business event is reported.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn Limited submitted the mandatory quarterly compliance certificate under SEBI Regulation 74(5) regarding dematerialization of shares for the quarter ended September 30, 2026.
Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn Ltd held its 45th Annual General Meeting on September 30, 2026, to deliberate on ordinary and special business resolutions.
Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn issued a corrigendum to its 45th AGM notice, updating the preferential issue resolution regarding share price, issue size, and allottee details.
Gujarat Themis Biosyn Acquisition Worth ₹1,300 Cr
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
- Value
- ₹1,300 Cr
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr